EGFR and breast cancer: In cancer cells, including breast cancer, FAS overexpression leads to de novo lipogenesis, incorporating lipids into the lipid rafts of tyrosine kinase membrane receptors, such as the EGFR family, triggering oncogenic signaling pathways that promote cell survival, proliferation, migration, and invasion.